These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 34714110)

  • 21. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.
    Blair HA
    Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Al-Sawaf O; Gentile B; Devine J; Zhang C; Sail K; Tandon M; Fink AM; Kutsch N; Wendtner CM; Eichhorst B; Hallek M; Fischer K
    Am J Hematol; 2021 Sep; 96(9):1112-1119. PubMed ID: 34050972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View.
    Do N; Thielen FW
    Value Health; 2023 Apr; 26(4):477-486. PubMed ID: 36375678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R; Redekop WK
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
    J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
    Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
    J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States.
    Munir T; Genovez V; Genestier V; Ryan K; Liljas B; Gaitonde P
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):579-589. PubMed ID: 36987886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
    Singh M; Mealing S; Baculea S; Cote S; Whelan J
    J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
    Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
    N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
    Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
    JCO Oncol Pract; 2024 Aug; 20(8):1132-1139. PubMed ID: 38626366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
    Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
    J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 37. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Niemann CU; Munir T; Moreno C; Owen C; Follows GA; Benjamini O; Janssens A; Levin MD; Robak T; Simkovic M; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Sinet P; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Kater AP
    Lancet Oncol; 2023 Dec; 24(12):1423-1433. PubMed ID: 37944541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Paquete AT; Miguel LS; Becker U; Pereira C; Pinto CG
    Appl Health Econ Health Policy; 2017 Aug; 15(4):501-512. PubMed ID: 28342061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
    Matasar M; Sanchez Alvarez J; Parisé H; Zuk E; Di Maio D; Shapouri S; Kim E; Lin SW
    J Med Econ; 2024; 27(1):766-776. PubMed ID: 38712895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
    Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
    Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.